Intervention to Reduce Perceived Cognitive Impairment in Multiple Sclerosis
Intervention to Reduce Distress from Perceived Cognitive Impairment in Multiple Sclerosis
1 other identifier
interventional
51
1 country
1
Brief Summary
Multiple sclerosis (MS) is among the most prevalent autoimmune diseases among young and middle-aged adults. Up to 65% of MS patients experience objective cognitive impairment including problems with information processing speed, memory, and executive functioning. However, patients commonly overestimate the extent of their cognitive dysfunction which can result in inaccurate perceptions of their true cognitive abilities. Exaggerated perceptions of cognitive impairment are predictive of future decline and associated with depression, anxiety, and reduced quality of life. Despite this, no study has examined an intervention aimed at changing misperceptions related to perceived cognitive impairment in MS when objective measures are incongruent with self-reported cognitive symptoms. The purpose of the present study is to develop and pilot a brief intervention for MS patients who perceive cognitive impairment, but perform in the normal or expected range on objective measures of cognition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable multiple-sclerosis
Started Mar 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 12, 2018
CompletedStudy Start
First participant enrolled
March 26, 2018
CompletedFirst Posted
Study publicly available on registry
March 26, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 15, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2019
CompletedDecember 6, 2024
November 1, 2020
1.4 years
March 12, 2018
December 3, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Feasibility and Acceptability Questionnaire
All participants complete a feasibility and acceptability questionnaire upon study completion. The questionnaire will address satisfaction with study participation, effectiveness and convenience of the intervention, and short answer questions on newly acquired information, application of information learned, and feelings about the new information. Participants will also be asked if they perceived the intervention as helpful and if they would be willing to recommend it to other MS patients. This measure will be scored quantitatively, ranging from 0-85 possible points, where higher scores indicated greater feasibility and acceptability of the intervention.
5 minutes
Secondary Outcomes (2)
Cognition Quiz
5 minutes
Perceived Cognitive Impairment-Distress (PCI-D)
5 minutes
Study Arms (2)
Cognitive Feedback and Psychoeducation (CFP)
EXPERIMENTALParticipants assigned to the cognitive feedback and psychoeducation (CFP) treatment group will watch a brief video integrating both neuropsychological test feedback and psychoeducation. The computerized intervention will cover MS disease-related information, define objective cognition, explain neuropsychological assessment, and inform patients of their cognitive test performance outcomes. The CFP intervention will also define and explain perceived cognition and subjective measures of cognition, and compare objective performance on neuropsychological tests to a subjective measure of perceived cognition. The intervention will also discuss emotion, attention, and misattribution related to PCI. The proposed intervention will incorporate expert testimony on MS disease course and related symptomology and interpretations of neuropsychological test performance.
Healthy Eating Habits (HEH)
ACTIVE COMPARATORThe control group, healthy eating habits (HEH) group, will watch a brief psychoeducational video of same length in time as the treatment group. The control intervention will include information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The proposed control intervention will include expert testimony from a nutritionist and expert dietician.
Interventions
The customary practice of providing feedback on neuropsychological test performance can address patient misperceptions of cognitive impairment by distinguishing between perceived and objective neuropsychological test performance. Explaining how normative data is derived by comparison to same age peers, patients are able to better understand their current cognitive functioning. The proposed intervention will employ both psychoeducation and neuropsychological feedback for participants assigned to the treatment group, and psychoeducation for participants assigned to the control group. Both groups will watch 3 brief videos (exactly the same length in time) and answer two qualitative questions following each video.
Information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The control intervention will include expert testimony from a nutritionist and expert dietician.
Eligibility Criteria
You may qualify if:
- diagnosis of MS by a board-certified neurologist
- a total score \> 40 on the Perceived Deficits Questionnaire (PDQ) based on previous research that identifies this cutoff score as clinically significant in the MS population and two standard deviations below average in the general population (Ruth Ann Marrie, Gordon J. Chelune, Deborah M. Miller, \& Jeffrey A. Cohen, 2005)
- score in the low average or better range on the Wechsler Test of Adult Reading (WTAR)
- average score equal to or greater than the 16th percentile on the Hopkins Verbal Learning Test (HVLT), Symbol Digit Modalities Test (SDMT), Controlled Oral Word Association Test (COWAT), and Wisconsin Card Sorting Task (WCST)
- average T score on the HVLT, SDMT, COWAT, and WCST no more than one standard deviation below the WTAR T score
- access to a computer and a personal email account
- English-speaking
You may not qualify if:
- no severe sensory, motor, physical, or neurological impairment that would make participation in the study insurmountable
- no history of nervous system disorder other than MS
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Missouri, Kansas Citylead
- University of Kansascollaborator
Study Sites (1)
University of Kansas Department of Neurology
Kansas City, Kansas, 66160, United States
Related Publications (23)
Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler. 2001 Oct;7(5):340-4. doi: 10.1177/135245850100700511.
PMID: 11724451BACKGROUNDKujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain. 1997 Feb;120 ( Pt 2):289-97. doi: 10.1093/brain/120.2.289.
PMID: 9117376BACKGROUNDBeier M, Amtmann D, Ehde DM. Beyond depression: Predictors of self-reported cognitive function in adults living with MS. Rehabil Psychol. 2015 Aug;60(3):254-62. doi: 10.1037/rep0000045. Epub 2015 Jul 20.
PMID: 26192051BACKGROUNDBenedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, Weinstock-Guttman B. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006 Jul;12(4):549-58. doi: 10.1017/s1355617706060723.
PMID: 16981607BACKGROUNDOlazaran J, Cruz I, Benito-Leon J, Morales JM, Duque P, Rivera-Navarro J. Cognitive dysfunction in multiple sclerosis: methods and prevalence from the GEDMA Study. Eur Neurol. 2009;61(2):87-93. doi: 10.1159/000177940. Epub 2008 Nov 28.
PMID: 19039226BACKGROUNDKinsinger SW, Lattie E, Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology. 2010 Sep;24(5):573-80. doi: 10.1037/a0019222.
PMID: 20804245BACKGROUNDBenedict RH. Effects of using same- versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis. J Int Neuropsychol Soc. 2005 Oct;11(6):727-36. doi: 10.1017/S1355617705050782.
PMID: 16248908BACKGROUNDBruce JM, Bruce AS, Hancock L, Lynch S. Self-reported memory problems in multiple sclerosis: influence of psychiatric status and normative dissociative experiences. Arch Clin Neuropsychol. 2010 Feb;25(1):39-48. doi: 10.1093/arclin/acp092. Epub 2009 Dec 3.
PMID: 19959565BACKGROUNDKalmar JH, Gaudino EA, Moore NB, Halper J, Deluca J. The relationship between cognitive deficits and everyday functional activities in multiple sclerosis. Neuropsychology. 2008 Jul;22(4):442-9. doi: 10.1037/0894-4105.22.4.442.
PMID: 18590356BACKGROUNDRao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991 May;41(5):692-6. doi: 10.1212/wnl.41.5.692.
PMID: 1823781BACKGROUNDBasso MR, Shields IS, Lowery N, Ghormley C, Combs D, Arnett PA, Johnson J. Self-reported executive dysfunction, neuropsychological impairment, and functional outcomes in multiple sclerosis. J Clin Exp Neuropsychol. 2008 Nov;30(8):920-30. doi: 10.1080/13803390801888733.
PMID: 18608679BACKGROUNDMiddleton LS, Denney DR, Lynch SG, Parmenter B. The relationship between perceived and objective cognitive functioning in multiple sclerosis. Arch Clin Neuropsychol. 2006 Aug;21(5):487-94. doi: 10.1016/j.acn.2006.06.008. Epub 2006 Aug 1.
PMID: 16879944BACKGROUNDAkbar N, Honarmand K, Feinstein A. Self-assessment of cognition in Multiple Sclerosis: the role of personality and anxiety. Cogn Behav Neurol. 2011 Sep;24(3):115-21. doi: 10.1097/WNN.0b013e31822a20ae.
PMID: 21904202BACKGROUNDAkbar N, Honarmand K, Kou N, Feinstein A. Validity of a computerized version of the symbol digit modalities test in multiple sclerosis. J Neurol. 2011 Mar;258(3):373-9. doi: 10.1007/s00415-010-5760-8. Epub 2010 Oct 6.
PMID: 20924594BACKGROUNDCull A, Hay C, Love SB, Mackie M, Smets E, Stewart M. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer. 1996 Nov;74(10):1674-9. doi: 10.1038/bjc.1996.608.
PMID: 8932354BACKGROUNDSawrie SM, Martin RC, Kuzniecky R, Faught E, Morawetz R, Jamil F, Viikinsalo M, Gilliam F. Subjective versus objective memory change after temporal lobe epilepsy surgery. Neurology. 1999 Oct 22;53(7):1511-7. doi: 10.1212/wnl.53.7.1511.
PMID: 10534260BACKGROUNDSawrie SM, Marson DC, Boothe AL, Harrell LE. A method for assessing clinically relevant individual cognitive change in older adult populations. J Gerontol B Psychol Sci Soc Sci. 1999 Mar;54(2):P116-24. doi: 10.1093/geronb/54b.2.p116.
PMID: 10097774BACKGROUNDvan Gorp WG, Satz P, Hinkin C, Selnes O, Miller EN, McArthur J, Cohen B, Paz D. Metacognition in HIV-1 seropositive asymptomatic individuals: self-ratings versus objective neuropsychological performance. Multicenter AIDS Cohort Study (MACS). J Clin Exp Neuropsychol. 1991 Sep;13(5):812-9. doi: 10.1080/01688639108401091.
PMID: 1955533BACKGROUNDMaor Y, Olmer L, Mozes B. The relation between objective and subjective impairment in cognitive function among multiple sclerosis patients--the role of depression. Mult Scler. 2001 Apr;7(2):131-5. doi: 10.1177/135245850100700209.
PMID: 11424633BACKGROUNDArnett PA, Rao SM, Grafman J, Bernardin L, Luchetta T, Binder JR, Lobeck L. Executive functions in multiple sclerosis: an analysis of temporal ordering, semantic encoding, and planning abilities. Neuropsychology. 1997 Oct;11(4):535-44. doi: 10.1037//0894-4105.11.4.535.
PMID: 9345697BACKGROUNDMittenberg W, Canyock EM, Condit D, Patton C. Treatment of post-concussion syndrome following mild head injury. J Clin Exp Neuropsychol. 2001 Dec;23(6):829-36. doi: 10.1076/jcen.23.6.829.1022.
PMID: 11910547BACKGROUNDBruce JM, Bruce AS, Arnett PA. Response variability is associated with self-reported cognitive fatigue in multiple sclerosis. Neuropsychology. 2010 Jan;24(1):77-83. doi: 10.1037/a0015046.
PMID: 20063948BACKGROUNDCarone DA. But the Scores Don't Show How I Really Function: A Feedback Method to Reveal Cognitive Distortions Regarding Normal Neuropsychological Test Performance. Appl Neuropsychol Adult. 2017 Mar-Apr;24(2):160-168. doi: 10.1080/23279095.2015.1116074. Epub 2016 Apr 4.
PMID: 27045631BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Jared Bruce, PhD
UMKC Faculty
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- 2, 4, and 6 blocked randomization (by gender) was conducted via computer generator. Group assignment was specified and sealed in individual envelopes by a study coordinator who is not involved in the current project. After participants are enrolled and complete the baseline evaluation, the appropriate envelope will be selected, based on gender, containing group assignment, and the subsequent intervention will be administered. Group assignment is not established until after the baseline evaluation has been conducted. Determining randomization will take place at a separate location from the recruitment/baseline site. No study member will have direct contact with participants following the baseline evaluation since the intervention is computerized and replies on emailing the study link to complete the intervention.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
March 12, 2018
First Posted
March 26, 2019
Study Start
March 26, 2018
Primary Completion
August 15, 2019
Study Completion
September 1, 2019
Last Updated
December 6, 2024
Record last verified: 2020-11
Data Sharing
- IPD Sharing
- Will not share